Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Feb;2(1):21-31.
doi: 10.1002/cam4.57. Epub 2013 Feb 3.

Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA

Affiliations

Gene expression of the IGF pathway family distinguishes subsets of gastrointestinal stromal tumors wild type for KIT and PDGFRA

Carol Beadling et al. Cancer Med. 2013 Feb.

Abstract

Gastrointestinal stromal tumors (GISTs) arise from the interstitial cells of Cajal (ICCs) and are the most common mesenchymal neoplasm of the gastrointestinal tract. While the majority of GISTs harbor activating mutations in either the v-kit Hardy-Zuckerman feline sarcoma viral oncogene homolog (KIT) or platelet-derived growth factor receptor alpha (PDGFRA) tyrosine kinases, approximately 10-15% of adult GISTs and 85% of pediatric GISTs lack such mutations. These "wild-type" GISTs have been reported to express high levels of the insulin-like growth factor 1 receptor (IGF1R), and IGF1R-targeted therapy of wild-type GISTs is being evaluated in clinical trials. However, it is not clear that all wild-type GISTs express IGF1R, because studies to date have predominantly focused on a particular subtype of gastric wild-type GIST that is deficient in the mitochondrial succinate dehydrogenase (SDH) complex. This study of a series of 136 GISTs, including 72 wild-type specimens, was therefore undertaken to further characterize wild-type GIST subtypes based on the relative expression of transcripts encoding IGF1R. Additional transcripts relevant to GIST biology were also evaluated, including members of the IGF-signaling pathway (IGF1, IGF2, and insulin receptor [INSR]), neural markers (CDH2[CDH: Cadherin], neurofilament, light polypeptide, LHX2 [LHX: LIM homeobox], and KIRREL3 [KIRREL: kin of IRRE like]), KIT, PDGFRA, CD34, and HIF1A. Succinate dehydrogenase complex, subunit B protein expression was also assessed as a measure of SDH complex integrity. In addition to the previously described SDH-deficient, IGF1R(high) wild-type GISTs, other SDH-intact wild-type subpopulations were defined by high relative expression of IGF1R, neural markers, IGF1 and INSR, or low IGF1R coupled with high IGF2. These results underscore the complexity and heterogeneity of wild-type GISTs that will need to be factored into molecularly-targeted therapeutic strategies.

Keywords: Gastrointestinal stromal tumor; IGF1R; wild type.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Relative KIT, PDGFRA, and IGF1R expression in KIT-mutant, PDGFRA-mutant, and wild-type GISTs. Target gene expression was measured in 138 GIST specimens by RT-PCR relative to the reference GAPDH. Values are expressed as the percent ratio relative to GAPDH, and depict the mean ± standard deviation for each GIST subtype. PDGFRA, platelet-derived growth factor receptor alpha; IGF1R, insulin-like growth factor 1 receptor; GIST, gastrointestinal stromal tumor; RT-PCR, real-time polymerase chain reaction.
Figure 2
Figure 2
Gene expression clusters define GIST subtypes. Self-organizing cluster analysis of the relative expression of 14 target genes relative to GAPDH identified five expression groups among 138 GIST specimens. Red indicates high relative expression and green indicates low relative expression. Location of the primary tumor is listed as stomach, small intestine, other, or unknown. SDHB immunohistochemistry was performed on 82 of the specimens, and was categorized as intact or deficient, as indicated. KIT and PDGFRA mutation status are illustrated in blue or orange, respectively, with nine indicating KIT exon 9 mutations. Pediatric specimens are indicated by arrows. GIST, gastrointestinal stromal tumor; PDGFRA, platelet-derived growth factor receptor alpha.
Figure 3
Figure 3
Subpopulations of wild-type and KIT-mutant GISTs. (a) Adult wild-type GISTs are segregated into four groups based on the expression levels of the IGF1R, neural marker, INSR, KIT, CD34 and IGF2 genes, and SDHB protein. Pediatric GISTs most closely resemble the adult wild-type GISTs with high relative expression of IGF1R, neural markers, INSR, KIT, and CD34, and low relative expression of IGF2. SDHB protein was detected in 16/19 IGF1Rhigh adult wild-type GISTs. (b) Some KIT-mutant GISTs exhibit similarities in relative CD34 and INSR expression compared with adult wild-type IGF1Rlow GISTs. GIST, gastrointestinal stromal tumor; IGF1R, insulin-like growth factor 1 receptor.

Similar articles

Cited by

References

    1. Corless C. L., Barnett C. M., Heinrich M. C. Gastrointestinal stromal tumours: origin and molecular oncology. Nat. Rev. Cancer. 2011;11:865–878. - PubMed
    1. Heinrich M. C., Corless C. L., Duensing A., McGreevey L., Chen C. J., Joseph N. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710. - PubMed
    1. Janeway K. A., Liegl B., Harlow A., Le C., Perez-Atayde A., Kozakewich H. Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors. Cancer Res. 2007;67:9084–9088. - PubMed
    1. Heinrich M. C., Corless C. L., Demetri G. D., Blanke C. D., von Mehren M., Joensuu H. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. 2003;21:4342–4349. - PubMed
    1. Debiec-Rychter M., Sciot R., Le C. A., Schlemmer M., Hohenberger P., van Oosterom A. T. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer. 2006;42:1093–1103. - PubMed

Publication types

MeSH terms

Substances